Andrea Lobo,  —

Blood levels of angiopoietin-2, a marker of blood vessel damage, may help predict treatment response and outcomes in pulmonary arterial hypertension (PAH), according to a new study from researchers in the U.S. Levels of D-dimer, a marker of blood clot formation, were also increased in PAH patients, the study…

Indicators of high blood sugar levels, particularly stress hyperglycemia ratio (SHR), may predict clinical worsening in people with idiopathic pulmonary arterial hypertension, a study in China indicates. Clinical worsening was defined as the first occurrence of lung transplant, being rehospitalized due to heart failure, or death from any cause.

A new educational campaign aims to raise awareness of pulmonary arterial hypertension (PAH) symptoms, with the goal of accelerating diagnosis and improving treatment. The American Lung Association campaign has the support of Merck, which markets Winrevair (sotatercept), a medication approved this year in the U.S. and…

Abnormalities in blood levels of various microRNAs (miRNAs) — small RNA molecules that regulate other genes in protein production — may contribute to the development and progression of chronic thromboembolic pulmonary…

A new device to deliver inhaled nitric oxide gas to newborns with pulmonary hypertension (PH), is now available for use in hospital neonatal intensive care units (NICUs) across the U.S. The rollout follows recent approval from the U.S. Food and Drug Administration of the next-generation device, the INOmax…

Exosomes, a type of small vesicle released by mesenchymal stem cells (MSCs), helped reduce vascular remodeling and ease pulmonary hypertension (PH) symptoms in a rat model of the disease, a study found. Exosome effects were tied to a modulation of the NF-kB/BMP pathway involved in vascular remodeling, a set…

Liquidia has expanded a license agreement with Pharmosa Biopharm, acquiring rights to market L606, a potential inhaled formulation of treprostinil now in a Phase 3 study, across Europe, Japan, and other regions as well as in North America. The two-part and open-label Phase 3 clinical…

The use of selenium supplements — an essential mineral naturally present in many foods and added to others — reduced blood vessel remodeling, a hallmark of pulmonary arterial hypertension (PAH), in the lung, according to a new study. Selinium has antioxidant properties and may help protect cells from damage.

Cereno Scientific’s investigational therapy CS014 was found to reverse remodeling, meaning alterations in structure and arrangement, of pulmonary arteries in a preclinical model of pulmonary arterial hypertension (PAH). According to the company, the new preclinical data “provide the most compelling evidence to date that CS014 offers a…

Oral carnitine supplements were well tolerated and blood levels of the molecule increased in people with pulmonary arterial hypertension (PAH), a pilot study shows. Carnitine transports fatty acids — the building blocks of fatty molecules…

Treatment with Adempas (riociguat) is generally safe and effective for people with pulmonary arterial hypertension (PAH) and coexisting cardiometabolic conditions, or those that affect the heart and metabolism, according to a pooled analysis of clinical trials. “Efficacy and risk assessment results suggest that [Adempas] can be beneficial for…

The European Commission has granted orphan medicinal product designation to Cereno Scientific’s CS1 for the treatment of people with pulmonary arterial hypertension (PAH). This designation is given to medications for life-threatening or chronically debilitating diseases, affecting up to five per 10,000 individuals in the European Union (EU), or…